Aussie digital health company hits new milestone in AstraZeneca partnership

Pharma News: Fewer than 50% of asthma patients adhere to their prescribed preventative medications. An Australian digital health company has received US Food and Drug Administration (FDA) approval for its device monitoring technology to enhance outcomes for patients with asthma and chronic obstructive pulmonary disease (COPD).

Adherium’s Hailie Smartinhaler is designed to be compatible with AstraZeneca’s Airsupra (albuterol/budesonide) and Breztri (budesonide/glycopyrrolate/formoterol fumarate) inhaler devices. Airsupra is a rescue medication for asthma patients and Breztri is a triple combination therapy for COPD patients.

AstraZeneca has successfully used the technology in clinical trials and has piloted its use in programs to support patients in the management of their respiratory conditions.  

The Bluetooth-enabled Hailie sensor attaches to the inhaler and is then paired with the Hailie app. The system is designed to help with treatment adherence by tracking medication use and reminding patients if a dose is missed. 

Patients are able to share adherence reports with clinicians by uploading the data to a secure cloud-based portal. This remote patient management platform allows healthcare providers to review the patient’s medication usage and make treatment decisions based on real-time data.

Adherium CEO, Paul Mastoridis, said “Our mission at Adherium has always been to revolutionise the way respiratory conditions are managed. By securing FDA clearance for our Smartinhaler with Airsupra and Breztri, we’re bringing that vision to life, offering patients and healthcare providers a powerful tool in the fight against chronic respiratory diseases.”

Allergist Dr Bill McCann commented on the launch, saying “The combination of the Hailie Smartinhaler with Airsupra and Breztri devices represents a leap forward in our ability to treat and manage asthma and COPD.

“This integration allows for a more nuanced understanding of patient needs and the ability to adjust treatments in real-time, which is invaluable in achieving optimal patient outcomes.”

In reimagining healthcare across the entire patient journey, Health Industry Hub^TM is the only one-stop-hub bringing the diversity of Pharma, MedTech, Diagnostics & Biotech sectors together to inspire meaningful change.

The content on Health Industry Hub is copyright protected and should only be accessed under individual user licenses. To subscribe, please click here and visit T&Cs here.